Oramed Pharmaceuticals Stock Price, News & Analysis

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) is a clinical-stage pharmaceutical company in the pharmaceutical preparation manufacturing industry that focuses on oral delivery solutions for drugs currently delivered via injection. The company describes itself as a platform technology pioneer in this field, built around its proprietary Protein Oral Delivery (POD™) technology, which is designed to protect drug integrity and increase absorption when administered orally.

According to multiple company disclosures, Oramed’s POD™ platform underpins its work on oral formulations of injectable therapies, including a refined oral insulin program. The company has reported extensive research and development efforts to transform injectable therapies into oral medications, and has developed oral dosage forms intended to withstand the harsh environment of the stomach and deliver active biological agents such as insulin.

Business focus and technology platform

Oramed’s core business is the research and development of oral drug delivery platforms. Its POD™ technology is repeatedly described in press releases and SEC filings as a novel protein oral delivery approach that aims to maintain drug stability and improve absorption in the gastrointestinal tract. This platform is used to support the company’s oral insulin program and other potential POD™-based oral drug delivery technologies.

The company has highlighted a refined oral insulin program based on analysis of prior Phase 2 and Phase 3 clinical data. In communications to shareholders, Oramed has discussed identifying high-responder subgroups in its clinical data and designing a U.S.-based trial to further evaluate its oral insulin formulation. These activities reflect its characterization as a clinical-stage pharmaceutical company focused on advancing oral insulin and related POD™-based candidates.

Strategic transactions and investment activities

Beyond internal R&D, Oramed has developed what it calls a diversified active investment portfolio across the biomedical landscape. Company press releases and shareholder letters describe structured investments in other healthcare and biotech businesses, including Scilex Holding Company, Alpha Tau Medical Ltd., BioXcel Therapeutics Inc., Pelthos Therapeutics Inc., and other earlier-stage biotech and real estate-related positions. These investments are presented as part of a broader strategy to deploy capital in opportunities that the company believes complement its core competencies.

In relation to Scilex, Oramed has entered into a senior secured promissory note, received repayments, and negotiated royalty interests on certain Scilex products. It has also entered into warrant and option agreements regarding Scilex equity. With Alpha Tau Medical, Oramed has entered into a strategic collaboration and service agreement, providing investor and shareholder outreach, business strategic guidance, and capital markets expertise, alongside a significant equity investment and governance role through board representation. These activities illustrate how Oramed combines its drug delivery platform with capital markets and business development capabilities.

Joint ventures and platform spin-outs

Oramed has announced and explored joint venture structures to further develop and commercialize its POD™ technology. In February 2025, the company disclosed definitive agreements to spin off its POD™ technology and oral insulin assets into a new joint venture, OraTech Pharmaceuticals Inc., with Hefei Tianhui Biotech Co., Ltd. (HTIT). Under those agreements, OraTech was expected to hold global marketing rights to Oramed’s POD™ oral protein delivery technology, receive capital contributions from Oramed and HTIT, and pursue Phase 3 trials and regulatory registrations for oral insulin in multiple territories.

Subsequent disclosures, however, indicate that this joint venture did not close as originally planned. In an October 2025 SEC filing, Oramed reported terminating the joint venture agreement and related supplemental agreement with HTIT after HTIT was unable to satisfy closing conditions. In later shareholder communications, Oramed stated that it planned to continue its oral insulin development program independently. These developments show how the company has adjusted its approach to partnering while maintaining its focus on oral insulin.

Strategic evolution and medical robotics exposure

In January 2026, Oramed announced binding agreements for a strategic transaction with Lifeward Ltd. (formerly ReWalk Robotics). Under this transaction, Oramed agreed to transfer its proprietary POD™ technology to Lifeward, while Oramed is expected to obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of specified conditions. Oramed also agreed to invest in Lifeward’s senior secured convertible notes with associated warrant coverage, and to manage an anticipated clinical trial under a clinical trial management agreement.

Through this transaction, Oramed describes itself as combining continued exposure to oral drug delivery innovation with participation in a revenue-generating medical robotics company. Lifeward designs, develops, and commercializes technologies such as the FDA-approved ReWalk® Personal Exoskeleton and AlterG® Anti-Gravity Systems, and Oramed has highlighted the revenue generated by these product lines in recent periods. Oramed has also disclosed that it will receive a percentage of net sales from the ReWalk franchise for a specified period. This structure positions Oramed as both a technology contributor and a significant shareholder in Lifeward.

Capital allocation, shareholder actions, and corporate governance

Oramed’s public communications emphasize its approach to capital allocation and shareholder returns. The company has discussed a stock repurchase program, cash dividends, and the potential distribution of equity in affiliated entities (such as OraTech, when that transaction was contemplated) to its shareholders. In January 2026, Oramed announced a cash dividend payment funded with surplus capital, following returns from its Scilex investment. In November 2025, the Board of Directors adopted a Rights Agreement and declared a dividend of common stock purchase rights designed, as described in the company’s press release and related SEC filing, to address potential hostile takeover scenarios and to support equal treatment of stockholders in such events.

SEC filings show that Oramed’s common stock, par value $0.012 per share, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades under the symbol ORMP on The Nasdaq Capital Market and on the Tel Aviv Stock Exchange. The company is incorporated in Delaware. Its filings also describe corporate actions such as amendments to its stock incentive plan and the outcomes of annual stockholder meetings.

Geographic footprint

Oramed states in multiple press releases that it has offices in the United States and Israel. SEC filings list its principal executive offices in New York, New York. These disclosures indicate that the company operates across at least these two jurisdictions as it advances its clinical programs and investment activities.

Position within the pharmaceutical preparation manufacturing sector

Within the broader manufacturing sector, Oramed is classified under pharmaceutical preparation manufacturing. Its differentiation, based on its own descriptions, lies in its focus on oral delivery of drugs that are typically administered by injection, and in its use of the POD™ platform for protein and other biologic therapies. The company’s activities span clinical development, strategic partnerships, and financial investments in other biomedical and medical technology companies.

FAQs about Oramed Pharmaceuticals Inc. (ORMP)

• What does Oramed Pharmaceuticals do?
  Oramed Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on developing oral delivery solutions for drugs that are currently delivered via injection. It describes itself as a platform technology pioneer built around its Protein Oral Delivery (POD™) technology, which is designed to protect drug integrity and increase absorption.
• What is Oramed’s POD™ technology?
  According to the company, its Protein Oral Delivery (POD™) technology is a novel oral delivery platform for protein and other injectable drugs. It is designed to protect the integrity of the drug and enhance absorption when administered orally, and it underpins Oramed’s oral insulin program and other POD™-based candidates.
• What is Oramed’s oral insulin program?
  Oramed has developed an oral insulin program based on its POD™ technology. The company has reported conducting Phase 2 and Phase 3 clinical trials and later focusing on high-responder subgroups identified in its data. It has discussed initiating a U.S.-based trial to further evaluate its refined oral insulin formulation.
• On which exchanges is ORMP stock traded?
  SEC filings state that Oramed’s common stock, par value $0.012 per share, is registered under Section 12(b) of the Exchange Act and trades under the symbol ORMP on The Nasdaq Capital Market and on the Tel Aviv Stock Exchange.
• How does Oramed describe its investment strategy?
  In shareholder letters and press releases, Oramed describes building a diversified active investment portfolio across the biomedical landscape. It has made structured investments in companies such as Scilex Holding Company, Alpha Tau Medical Ltd., BioXcel Therapeutics Inc., and Pelthos Therapeutics Inc., as well as in real estate and loans with real estate collateral, while continuing to advance its oral insulin program.
• What is the relationship between Oramed and Lifeward Ltd.?
  In January 2026, Oramed announced binding agreements with Lifeward Ltd. under which Oramed will transfer its POD™ technology to Lifeward and is expected to obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain conditions. Oramed will invest in Lifeward’s senior secured convertible notes with warrant coverage and is expected to manage an anticipated clinical trial related to the oral delivery platform.
• Did Oramed complete its joint venture with HTIT for OraTech?
  Oramed initially announced a joint venture with Hefei Tianhui Biotech Co., Ltd. (HTIT) to form OraTech Pharmaceuticals Inc. and spin out its POD™ technology. However, an October 2025 SEC filing reports that Oramed terminated the joint venture agreement and supplemental agreement after HTIT was unable to satisfy closing conditions. Oramed has stated that it plans to continue its oral insulin program independently.
• Does Oramed pay dividends or conduct share repurchases?
  Company communications describe both share repurchase and dividend actions. Oramed has announced a stock repurchase program and, in January 2026, a cash dividend payment funded with surplus capital. It has also discussed potential one-time dividends in the context of planned spin-offs and has adopted a Rights Agreement that includes a dividend of common stock purchase rights.
• Where is Oramed based?
  Oramed’s SEC filings list its principal executive offices in New York, New York, and its press releases state that the company has offices in the United States and Israel.
• What sector and industry is Oramed classified under?
  Oramed is categorized in the manufacturing sector, specifically under pharmaceutical preparation manufacturing. Its activities center on oral drug delivery technologies and related clinical and investment initiatives.